Latham & Watkins Advises BridgeBio Pharma in US$750 Million Non-Dilutive Debt Financing

BridgeBio Pharma (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, has announced that it has executed a definitive credit facility agreement with a syndicate of lenders for up to US$750 million in financing. This facility, combined with the Company’s existing cash balance as of September 30, 2021, provides access to over US$1.2 billion to advance the Company’s pipeline programs, support commercialization efforts, and enable the Company to pursue strategic business development opportunities. As structured, this financing is expected to fully fund BridgeBio’s portfolio of more than 30 drug development and discovery programs into 2024, independent of near-term milestone readouts.

Latham & Watkins LLP represents BridgeBio in the transaction with a transactional team led by Bay Area partners Haim Zaltzman and Dan Van Fleet, with associates Ramin Montazeri and Tony Noh. Advice was also provided on public company financing matters by New York partner Reza Mojtabaee-Zamani, with associate Jack Neff; on regulatory matters by associate Chad Jennings; on tax matters by Los Angeles partner Eric Cho, with associate Mario Moreno; on UK finance matters by London partner James Chesterman, with associate Hafza Hussein; on investment funds regulatory matters by Chicago partner Nabil Sabki, with associate Jina Yun; and on corporate matters by associate Christopher Clark.